SEHK:1093Pharmaceuticals
Assessing CSPC Pharmaceutical Group (SEHK:1093) Valuation After Latest Regulatory Milestones and R&D Pipeline Advances
CSPC Pharmaceutical Group (SEHK:1093) has just made headlines with two R&D milestones. Its JSKN003 therapy gained Breakthrough Therapy Designation for advanced colorectal cancer, and SYH2061 secured clearance for clinical trials in China.
See our latest analysis for CSPC Pharmaceutical Group.
After a stellar run earlier this year, CSPC Pharmaceutical Group’s share price recently cooled off, dropping 18.4% over the past month and 22.7% in the last 90 days. Still, its year-to-date share price...